Clinical trialNCT04872478RecruitingPhase 1Interventional

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

SponsorMeryx, Inc.Enrollment50Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joshua Zeidner, MD
UNC Lineberger Comprehensive Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Melinda Pauley, MD
Emory University, Children's Healthcare of Atlanta
Principal Investigator
clinicaltrials.gov ↗
Thomas Alexander, MD
UNC Lineberger Comprehensive Cancer Center, Children's
Principal Investigator
clinicaltrials.gov ↗
William Blum, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University - Winship Cancer Center
Atlanta, Georgia, United States
Recruiting
Emory University, Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Neerav Shukla
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MRX-2843

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Apr 2022
Primary completion: 31 Jul 2026
Completion: 30 Sept 2026
Last update posted: 8 Jan 2026
Registered enrollment: 50
Registry id: NCT04872478

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.